Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MALARONE PEDIATRIC vs ARALEN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MALARONE PEDIATRIC is a fixed-dose combination of atovaquone and proguanil. Atovaquone selectively inhibits the mitochondrial electron transport chain of Plasmodium species at the cytochrome bc1 complex, collapsing mitochondrial membrane potential and disrupting pyrimidine synthesis. Proguanil is a prodrug converted to cycloguanil, which inhibits dihydrofolate reductase in the parasite, blocking DNA synthesis. The combination synergistically kills blood-stage schizonts and inhibits liver-stage hypnozoites of P. falciparum.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.
Treatment of acute, uncomplicated Plasmodium falciparum malaria,Prophylaxis of Plasmodium falciparum malaria
Treatment of uncomplicated malaria due to chloroquine-sensitive Plasmodium species,Prophylaxis of malaria in areas with chloroquine-sensitive parasites,Extraintestinal amebiasis,Treatment of discoid lupus erythematosus (off-label),Treatment of rheumatoid arthritis (off-label)
Adults: 250 mg atovaquone/100 mg proguanil orally once daily for 3 consecutive days for treatment; for prophylaxis, 250 mg/100 mg orally once daily starting 1-2 days before travel and continued for 7 days after leaving endemic area.
Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.
Atovaquone: terminal half-life 1.5-3 days (range 2-3 days in adults, longer in children). Proguanil: terminal half-life 12-21 hours (parent drug) and 14-23 hours (cycloguanil). Clinically, atovaquone's long half-life supports single daily dosing.
48-72 hours (terminal elimination half-life); prolonged to weeks with chronic dosing due to extensive tissue accumulation, especially in the liver, spleen, and melanin-containing tissues.
Atovaquone undergoes minimal metabolism, with glucuronidation as a minor pathway, and is primarily excreted unchanged in feces. Proguanil is hepatically metabolized via CYP2C19 to its active metabolite cycloguanil, and to a lesser extent by CYP3A4.
Hepatic metabolism via CYP2C8, CYP3A4, and CYP2D6 to desethylchloroquine and other metabolites.
Atovaquone: >90% excreted unchanged in feces via biliary elimination; <1% renal. Proguanil: ~40-60% excreted renally as unchanged drug and active metabolite cycloguanil; ~30% fecal.
Renal (~70% unchanged), with 10-20% in feces; biliary elimination is minor.
Atovaquone: >99% bound to plasma proteins. Proguanil: ~75% bound to plasma proteins.
50-60%, primarily to albumin and α1-acid glycoprotein.
Atovaquone: Vd ~0.6-1.0 L/kg (extensive tissue distribution). Proguanil: Vd ~0.2-0.5 L/kg.
50-100 L/kg; extensive tissue sequestration including erythrocytes, liver, spleen, and melanin-containing tissues like skin and retina.
Atovaquone: Oral bioavailability highly variable (range 10-50%) but improved with fatty food; ~23% in fasted state, increased ~2-fold with high-fat meal. Proguanil: Oral bioavailability ~70-90%.
Oral: ~70-80% (variable due to first-pass metabolism); intravenous: 100%.
For prophylaxis: If Cr Cl 30-50 m L/min, reduce dose to half the standard adult dose; if Cr Cl <30 m L/min, use alternative agent. For treatment: If Cr Cl 30-50 m L/min, reduce dose to half the standard adult dose; if Cr Cl <30 m L/min, use alternative agent.
Severe renal impairment (GFR <10 m L/min): reduce dose by 50% or increase dosing interval.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). For severe hepatic impairment (Child-Pugh C), use with caution due to limited data; no specific dose recommendation available.
Use with caution in patients with hepatic impairment; no specific dose adjustment guidelines available; contraindicated in severe hepatic disease or porphyria.
Children ≥5 kg: For treatment, 20 mg/kg atovaquone/8 mg/kg proguanil orally once daily for 3 days. For prophylaxis, 20 mg/kg atovaquone/8 mg/kg proguanil orally once daily. Dosing based on weight: 5-8 kg: pediatric tablet (62.5 mg/25 mg) daily; 9-10 kg: 1.5 pediatric tablets daily; 11-20 kg: 2 pediatric tablets daily; 21-30 kg: 3 pediatric tablets daily; 31-40 kg: 4 pediatric tablets daily; >40 kg: adult tablet (250 mg/100 mg) daily.
Prophylaxis: 5 mg base/kg orally once weekly (max 300 mg base). Treatment: 10 mg base/kg orally initially, then 5 mg base/kg at 6, 24, and 48 hours (max 600 mg base total).
No specific dose adjustment required based on age alone; use standard adult dosing, but consider renal function as older adults may have reduced creatinine clearance. Monitor for adverse effects, particularly gastrointestinal.
Start at lower end of dosing range due to increased risk of adverse effects (e.g., QT prolongation, retinal toxicity); monitor renal function.
None
No FDA black box warning.
Not recommended for severe malaria or cerebral malaria,May cause hypersensitivity reactions, including angioedema and anaphylaxis,Avoid in patients with severe renal impairment (Cr Cl <30 m L/min) due to risk of accumulation of proguanil,May cause hepatotoxicity; monitor liver function in prolonged use,May cause gastrointestinal disturbances; administer with food,Parasite resistance may develop; monitor for clinical failure
Retinopathy and irreversible retinal damage with prolonged use or high doses; requires baseline and periodic ophthalmologic exams,QT prolongation and ventricular arrhythmias, especially with concomitant QT-prolonging drugs or electrolyte abnormalities,Severe hypoglycemia including loss of consciousness,Neuropsychiatric effects including psychosis and suicidal ideation,Hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hypersensitivity to atovaquone, proguanil, or any component,Severe renal impairment (Cr Cl <30 m L/min) for prophylaxis,Concurrent use with rifampin or rifabutin (may reduce atovaquone levels)
Hypersensitivity to chloroquine or any 4-aminoquinoline,Pre-existing retinopathy or known maculopathy,Known G6PD deficiency (relative, use with caution),Concomitant use with strong QT-prolonging drugs (e.g., quinidine, procainamide)
Take with food or milk to increase atovaquone absorption. Avoid high-fat meals immediately before or after dosing as they may slightly delay absorption but overall increase bioavailability. No known significant food-drug interactions with proguanil.
Avoid grapefruit and grapefruit juice as they may increase drug levels and toxicity. Limit alcohol intake to reduce risk of liver toxicity. Administer with food to decrease gastrointestinal irritation. Avoid antacids containing aluminum or magnesium; separate by at least 4 hours.
MALARONE PEDIATRIC contains atovaquone and proguanil. Atovaquone is not teratogenic in animals, but proguanil is associated with increased risk of neural tube defects and other congenital anomalies if used in the first trimester. Data in humans are limited; it should only be used if benefit outweighs risk. Pregnancy category C.
Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) at high doses. Second and third trimesters: possible ototoxicity and retinal toxicity; use only for malaria prophylaxis or treatment when benefit outweighs risk.
Atovaquone and proguanil are excreted in breast milk in low concentrations, but no adverse effects have been reported. M/P ratio not established. Consider risk-benefit; caution in infants with G6PD deficiency. Discontinue breastfeeding or drug if infant develops hemolysis.
Chloroquine is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Amounts are unlikely to cause adverse effects in nursing infants. The American Academy of Pediatrics considers chloroquine compatible with breastfeeding. Monitor infant for potential ocular effects.
No specific dosing adjustments are recommended for pregnancy. However, pharmacokinetic changes in pregnancy (e.g., increased clearance) may require monitoring for therapeutic efficacy.
Increased volume of distribution and clearance during pregnancy may require higher doses for malaria prophylaxis (e.g., 400 mg base weekly) and treatment; therapeutic drug monitoring recommended for optimal dosing. No standard dose adjustment established; base dose on indication and clinical response.
Malarone Pediatric (atovaquone/proguanil) is indicated for prophylaxis and treatment of acute, uncomplicated P. falciparum malaria. Prophylaxis should start 1-2 days before travel, continued during stay, and for 7 days after leaving endemic area. Administer with food or milk to enhance absorption. Not recommended for children <5 kg. Avoid use for malaria treatment in patients with severe renal impairment (Cr Cl <30 m L/min). Monitor for signs of hepatotoxicity, especially in patients with pre-existing liver disease.
ARALEN HYDROCHLORIDE (chloroquine hydrochloride) is used for malaria prophylaxis and treatment, and for amebiasis. Monitor for retinal toxicity with long-term use; baseline and periodic ophthalmologic exams recommended. Caution in patients with hepatic disease, G6PD deficiency, or porphyria. May exacerbate psoriasis and myasthenia gravis. QT prolongation possible; avoid with other QT-prolonging drugs. Administer with food to reduce GI upset. For acute malaria, dose may be divided to improve tolerance. In severe malaria, use parenteral form with cardiac monitoring.
Take this medication exactly as prescribed, with food or milk to improve absorption and reduce stomach upset.,For prevention: start 1-2 days before entering malarious area, continue while there, and for 7 days after leaving.,Complete full course even if feeling better; do not skip doses.,Use additional protective measures like insect repellent and bed nets.,Contact doctor immediately if signs of malaria (fever, chills, headache) occur during or after travel.,Report any rash, mouth ulcers, easy bruising/bleeding, or yellowing of eyes/skin.,Keep out of reach of children; overdose can be fatal.
Take this medication exactly as prescribed; do not skip doses for malaria prophylaxis.,If vomiting occurs within 1 hour of a dose, contact your healthcare provider for instructions.,Report any vision changes, such as blurred vision or difficulty focusing, immediately.,Avoid alcohol and limit caffeine intake as they may increase gastrointestinal side effects.,Use effective contraception during treatment if you are of childbearing potential.,Do not take antacids or kaolin within 4 hours of this medication.,Seek medical attention if you experience signs of allergic reaction: rash, hives, swelling, or difficulty breathing.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MALARONE PEDIATRIC vs ARALEN HYDROCHLORIDE, answered by our medical review team.
MALARONE PEDIATRIC is a Antimalarial that works by MALARONE PEDIATRIC is a fixed-dose combination of atovaquone and proguanil. Atovaquone selectively inhibits the mitochondrial electron transport chain of Plasmodium species at the cytochrome bc1 complex, collapsing mitochondrial membrane potential and disrupting pyrimidine synthesis. Proguanil is a prodrug converted to cycloguanil, which inhibits dihydrofolate reductase in the parasite, blocking DNA synthesis. The combination synergistically kills blood-stage schizonts and inhibits liver-stage hypnozoites of P. falciparum.. ARALEN HYDROCHLORIDE is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MALARONE PEDIATRIC and ARALEN HYDROCHLORIDE depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MALARONE PEDIATRIC is: Adults: 250 mg atovaquone/100 mg proguanil orally once daily for 3 consecutive days for treatment; for prophylaxis, 250 mg/100 mg orally once daily starting 1-2 days before travel and continued for 7 days after leaving endemic area.. The standard adult dose of ARALEN HYDROCHLORIDE is: Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MALARONE PEDIATRIC and ARALEN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MALARONE PEDIATRIC is classified as Category C. MALARONE PEDIATRIC contains atovaquone and proguanil. Atovaquone is not teratogenic in animals, but proguanil is associated with increased risk of neural tube defects and other con. ARALEN HYDROCHLORIDE is classified as Category C. Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.